GlassScriptPhysician profile
Maithili Patel
NPI 1548997042
$1,557.33
in general payments reported to CMS, 2019-2025
14 companies · $716 in 2025
The $716 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $155 · 2023: $442 · 2024: $244 · 2025: $716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,402.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $455.48 | 2023-2025 | |
| Biotissue Holdings INC. | $157.84 | 2023-2025 | |
| Johnson & Johnson Vision Care, INC. | $141.45 | 2023 | Acuvue |
| Sight Sciences, INC. | $138.61 | 2022 | |
| Harrow Eye, LLC | $120.82 | 2024-2025 | Vevye |
| Sun Pharmaceutical Industries INC. | $119.47 | 2023 | Cequa |
| Tarsus Pharmaceuticals, INC. | $96.04 | 2025 | Xdemvy |
| Rxsight INC | $93.64 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Dompe US, INC. | $59.31 | 2025 | Oxervate |
| Bausch & Lomb Americas INC. | $44.81 | 2023-2024 | Miebo, Envista Mx60 Iol, Ic-8 Apthera Iol |
| Glaukos Corporation | $43.03 | 2024 | Idose |
| Amgen INC. | $31.75 | 2025 | Tepezza |
| Oyster Point Pharma, INC. | $28.05 | 2025 | Tyrvaya |
| Alcon Vision LLC | $27.03 | 2025 | Tryptyr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maithili Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.